Will ImmunityBio submit an sNDA/BLA for ANKTIVA in BCG-naive NMIBC to the FDA by December 31, 2026?
Current Prediction
Why This Question Matters
QUILT 2.005 BCG-naive label expansion is the single highest-value catalyst. The Regulatory Reader identified this as the key to expanding the addressable market from ~5K to ~25K+ patients. An FDA submission in 2026 would validate the clinical data and timeline. Delay or failure would constrain ANKTIVA to a limited market.
Prediction Distribution
Individual Predictions(9 runs)
QUILT 2.005 has 366 patients enrolled with positive interim data, but the trial is ongoing and full data is needed for submission. FDA submissions typically require 12-18 months of follow-up data after enrollment completion, plus compilation and filing time. 2026 submission requires everything to go optimally.
The FDA requested the interim analysis, suggesting engagement. If the full data is mature by mid-2026, a submission could occur in H2 2026. However, the RTF experience with QUILT-3.032 suggests the company may be more cautious about submission completeness.
Regulatory timelines in oncology are notoriously unpredictable. Even with positive interim data, the FDA may require longer follow-up for a new patient population. The company has strong incentive to file quickly but the regulatory process may not accommodate that urgency.
The interim data is strong (p=0.0455), enrollment is complete, and the company is highly motivated. Accelerated approval pathways exist for oncology indications with strong interim data. If the company pursues accelerated approval based on CR rate as a surrogate endpoint, submission could happen in 2026.
Positive interim but 2026 is aggressive. Need full data maturation, BLA/sNDA preparation, and pre-submission meeting with FDA. The QUILT-3.032 RTF experience may have made the company more cautious about filing readiness. Q1 2027 seems more realistic than Q4 2026.
Management stated plans for label expansion submissions in 2026. While management statements should be weighted against execution history (RTF on papillary), the BCG-naive data is substantially stronger. Assign ~38% probability.
Positive interim data but trial ongoing. 2026 submission requires fast data maturation and filing. Possible but not probable. ~35%.
Regulatory submissions take longer than companies expect. Even with positive data, the 2026 timeline is aggressive. 30% probability.
FDA engagement (requesting interim) suggests receptivity. Accelerated approval pathway could shorten timeline. But data maturation is the binding constraint. ~38%.
Resolution Criteria
Resolves YES if ImmunityBio publicly discloses (via 8-K, press release, or earnings call) that it has submitted a supplemental NDA or BLA to the FDA for ANKTIVA in BCG-naive NMIBC by December 31, 2026.
Resolution Source
ImmunityBio press releases, 8-K filings, or FDA acceptance letter disclosure
Source Trigger
QUILT 2.005 final data readout and regulatory submission
Full multi-lens equity analysis